Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025
Ocular Therapeutix (NASDAQ:OCUL), a biopharmaceutical company focused on retina treatments, has scheduled its Q2 2025 earnings conference call for Tuesday, August 5, 2025, at 8:00 AM ET. The company will discuss its business progress and financial results for the quarter ended June 30, 2025.
The call will be accessible via U.S. dial-in (1-877-407-9039), international dial-in (1-201-689-8470), and webcast. A replay will be available on the company's Investor Relations page for at least 30 days following the presentation.
Ocular Therapeutix (NASDAQ:OCUL), un'azienda biofarmaceutica specializzata in trattamenti per la retina, ha programmato la sua conference call per i risultati del secondo trimestre 2025 martedì 5 agosto 2025 alle 8:00 AM ET. Durante la chiamata verranno discussi i progressi aziendali e i risultati finanziari relativi al trimestre conclusosi il 30 giugno 2025.
La chiamata sarà accessibile tramite numero verde USA (1-877-407-9039), numero internazionale (1-201-689-8470) e webcast. La registrazione sarà disponibile sulla pagina Relazioni con gli Investitori della società per almeno 30 giorni dopo la presentazione.
Ocular Therapeutix (NASDAQ:OCUL), una compañía biofarmacéutica centrada en tratamientos para la retina, ha programado su conferencia telefónica de resultados del segundo trimestre de 2025 para el martes 5 de agosto de 2025 a las 8:00 AM ET. La empresa discutirá su progreso comercial y resultados financieros del trimestre finalizado el 30 de junio de 2025.
La llamada será accesible mediante línea telefónica en EE.UU. (1-877-407-9039), línea internacional (1-201-689-8470) y webcast. Una repetición estará disponible en la página de Relaciones con Inversionistas de la compañía durante al menos 30 días después de la presentación.
Ocular Therapeutix (NASDAQ:OCUL)은 망막 치료에 중점을 둔 바이오제약 회사로, 2025년 8월 5일 화요일 오전 8시(동부시간)에 2025년 2분기 실적 컨퍼런스 콜을 예정하고 있습니다. 회사는 2025년 6월 30일 종료된 분기의 사업 진행 상황과 재무 결과를 논의할 예정입니다.
콜은 미국 내 전화 접속(1-877-407-9039), 국제 전화 접속(1-201-689-8470), 웹캐스트를 통해 참여할 수 있습니다. 발표 후 최소 30일간 회사 투자자 관계 페이지에서 다시 듣기가 제공됩니다.
Ocular Therapeutix (NASDAQ:OCUL), une société biopharmaceutique spécialisée dans les traitements de la rétine, a programmé sa conférence téléphonique sur les résultats du deuxième trimestre 2025 le mardi 5 août 2025 à 8h00 ET. La société discutera de ses progrès commerciaux et de ses résultats financiers pour le trimestre clos le 30 juin 2025.
L'appel sera accessible via une ligne téléphonique américaine (1-877-407-9039), une ligne internationale (1-201-689-8470) et un webcast. Une rediffusion sera disponible sur la page Relations Investisseurs de l'entreprise pendant au moins 30 jours après la présentation.
Ocular Therapeutix (NASDAQ:OCUL), ein biopharmazeutisches Unternehmen mit Fokus auf Netzhautbehandlungen, hat seine Telefonkonferenz zu den Ergebnissen des zweiten Quartals 2025 für Dienstag, den 5. August 2025, um 8:00 Uhr ET angesetzt. Das Unternehmen wird den Geschäftsfortschritt und die Finanzergebnisse für das Quartal zum 30. Juni 2025 besprechen.
Der Anruf ist über die US-Einwahlnummer (1-877-407-9039), die internationale Einwahlnummer (1-201-689-8470) und per Webcast zugänglich. Eine Aufzeichnung wird auf der Investor-Relations-Seite des Unternehmens für mindestens 30 Tage nach der Präsentation verfügbar sein.
- None.
- None.
BEDFORD, Mass., July 29, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, August 5, 2025 at 8:00 AM ET to discuss recent business progress and financial results for the second quarter ended June 30, 2025.
Conference Call and Webcast Information:
Date: Tuesday, August 5, 2025, at 8:00 AM ET
Participant Dial-In (U.S.): 1-877-407-9039
Participant Dial-In (International): 1-201-689-8470
Webcast Access: Please click here
The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn, or X.
DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
When is Ocular Therapeutix (OCUL) reporting Q2 2025 earnings?
How can investors access OCUL's Q2 2025 earnings call?
What period will Ocular Therapeutix's earnings report cover?
How long will OCUL's Q2 2025 earnings webcast be available?
